• Insights from GSK's Chief Scientist on the Role of Technology in R&D

  • Jan 30 2025
  • Durée: 47 min
  • Podcast

Insights from GSK's Chief Scientist on the Role of Technology in R&D

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • "We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going to be massively compressed," Dr. Tony Wood, Chief Scientific Officer at GSK, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wood joins BI analyst Sam Fazeli to address the disconnect between market expectations for its future drugs in the context of GSK's R&D strategy and technology leverage. The company has five potential new drug approvals in 2025 and sees its early stage investments in AI and ML holding huge potential to catalyze future drug discovery and development.

    See omnystudio.com/listener for privacy information.
    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de Insights from GSK's Chief Scientist on the Role of Technology in R&D

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.